{"id":"https://openalex.org/W4282933540","doi":"https://doi.org/10.1158/1538-7445.am2022-lb190","title":"Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML","display_name":"Abstract LB190: Modulation of SPI1 transcriptional program contributes to the preclinical anti-tumor activity of SMARCA4/SMARCA2 ATPase inhibitors in AML","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282933540","doi":"https://doi.org/10.1158/1538-7445.am2022-lb190"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-lb190","doi":"https://doi.org/10.1158/1538-7445.am2022-lb190","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-lb190","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045201129","display_name":"Gabriel J. Sandoval","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriel J. Sandoval","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069979455","display_name":"Katharine Feldman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katharine Feldman","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021405846","display_name":"Sal Topal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sal Topal","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024517878","display_name":"Ammar Adam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ammar Adam","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018271642","display_name":"Hsin\u2010Jung Wu","orcid":"https://orcid.org/0009-0005-3474-6171","observed_orcids":["https://orcid.org/0009-0005-3474-6171","https://orcid.org/0009-0001-8502-2203"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hsin-Jung Wu","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083836044","display_name":"Darshan S. Sappal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Darshan Sappal","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073459416","display_name":"Luis Miguel Mendes Soares","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Luis M. Soares","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078970169","display_name":"David L. Lahr","orcid":"https://orcid.org/0000-0001-6283-0286","observed_orcids":["https://orcid.org/0000-0001-6283-0286"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David L. Lahr","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112319765","display_name":"Lan Xu","orcid":"https://orcid.org/0000-0002-7740-5482","observed_orcids":["https://orcid.org/0000-0002-7740-5482"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lan Xu","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055870186","display_name":"Rishi G. Vaswani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rishi G. Vaswani","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074139173","display_name":"Jordana Muwanguzi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordana Muwanguzi","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110381920","display_name":"Liyue Huang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liyue Huang","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084422325","display_name":"Jessica C. Piel","orcid":"https://orcid.org/0009-0003-8299-5370","observed_orcids":["https://orcid.org/0009-0003-8299-5370"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Piel","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mike Collins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mike Collins","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105367150","display_name":"Ho Man Chan","orcid":"https://orcid.org/0000-0002-1117-1230","observed_orcids":["https://orcid.org/0000-0002-1117-1230"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ho Man Chan","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046769048","display_name":"Michael J. Thomenius","orcid":"https://orcid.org/0000-0002-3357-7872","observed_orcids":["https://orcid.org/0000-0002-3357-7872"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael J. Thomenius","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086182257","display_name":"Steven F. Bellon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven F. Bellon","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088240960","display_name":"Ryan G. Kruger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan G. Kruger","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044857121","display_name":"Carl P. Decicco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carl P. Decicco","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079460736","display_name":"Richard C. Centore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard C. Centore","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5047249666","display_name":"Martin F. Hentemann","orcid":"https://orcid.org/0009-0008-5657-2151","observed_orcids":["https://orcid.org/0009-0008-5657-2151"]},"institutions":[{"id":"https://openalex.org/I4210164523","display_name":"Foghorn Therapeutics (United States)","ror":"https://ror.org/05j5rbv93","country_code":"US","type":"company","lineage":["https://openalex.org/I4210164523"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Hentemann","raw_affiliation_strings":["1Foghorn Therapeutics, Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Foghorn Therapeutics, Cambridge, MA","institution_ids":["https://openalex.org/I4210164523"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210164523"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"LB190","last_page":"LB190"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12820","display_name":"Chromatin Remodeling and Cancer","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.009100000374019146,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pu-1","display_name":"PU.1","score":0.9879999756813049},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.972000002861023},{"id":"https://openalex.org/keywords/ets-transcription-factors","display_name":"ETS transcription factors","score":0.8130000233650208},{"id":"https://openalex.org/keywords/transcriptional-regulation","display_name":"transcriptional regulation","score":0.6899999976158142},{"id":"https://openalex.org/keywords/cell-cycle-arrest","display_name":"cell cycle arrest","score":0.8410000205039978},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":1.0},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.7820000052452087},{"id":"https://openalex.org/keywords/hematopoietic-differentiation","display_name":"hematopoietic differentiation","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6276232004165649},{"id":"https://openalex.org/C80828422","wikidata":"https://www.wikidata.org/wiki/Q18031595","display_name":"SMARCA4","level":5,"score":0.5726287364959717},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.5314841270446777},{"id":"https://openalex.org/C83640560","wikidata":"https://www.wikidata.org/wiki/Q180951","display_name":"Chromatin","level":3,"score":0.48385870456695557},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.4665714502334595},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.4631371796131134},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4559313952922821},{"id":"https://openalex.org/C127561419","wikidata":"https://www.wikidata.org/wiki/Q224527","display_name":"Downregulation and upregulation","level":3,"score":0.44619283080101013},{"id":"https://openalex.org/C134320426","wikidata":"https://www.wikidata.org/wiki/Q901026","display_name":"Chromatin immunoprecipitation","level":5,"score":0.4149578809738159},{"id":"https://openalex.org/C167227067","wikidata":"https://www.wikidata.org/wiki/Q5113739","display_name":"Chromatin remodeling","level":4,"score":0.3263060450553894},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2910241484642029},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.2723134160041809},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.262222021818161},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.18052330613136292},{"id":"https://openalex.org/C101762097","wikidata":"https://www.wikidata.org/wiki/Q224093","display_name":"Promoter","level":4,"score":0.15594831109046936}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-lb190","doi":"https://doi.org/10.1158/1538-7445.am2022-lb190","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-lb190","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4362544003","https://openalex.org/W4310167630","https://openalex.org/W4389220735","https://openalex.org/W4282980852","https://openalex.org/W4389241551","https://openalex.org/W4393088769","https://openalex.org/W4386767064","https://openalex.org/W4405042172","https://openalex.org/W2913043165","https://openalex.org/W4392366741"],"abstract_inverted_index":{"Abstract":[0],"SPI1":[1,21,125,130,161,171,244],"(PU.1)":[2],"is":[3,36,78],"an":[4],"ETS":[5],"family":[6,66],"transcription":[7],"factor":[8],"that":[9,98,118,168],"plays":[10],"a":[11,45,73,177],"critical":[12,60],"role":[13],"in":[14,27,109,138,145,174,186,257],"hematopoietic":[15],"development":[16,183],"and":[17,43,71,90,93,114,157],"differentiation.":[18],"Regulation":[19],"of":[20,47,51,62,67,86,140,149,160,170,184,243,253,262],"expression":[22],"has":[23],"also":[24],"been":[25],"implicated":[26],"Acute":[28],"Myeloid":[29],"Leukemia":[30],"(AML)":[31],"oncogenesis,":[32],"though":[33],"its":[34],"mechanism":[35],"incompletely":[37],"understood.":[38],"Previously":[39],"we":[40,96,151],"have":[41],"identified":[42],"characterized":[44],"series":[46],"novel":[48],"dual":[49],"inhibitors":[50,256],"the":[52,63,84,124,181,249,263],"SMARCA4/SMARCA2":[53,75,254],"ATPases":[54],"(also":[55],"referred":[56],"to":[57,104,248],"as":[58],"BRG1/BRM),":[59],"components":[61],"BAF":[64,105,119],"(mSWI/SNF)":[65],"chromatin":[68],"remodeling":[69],"complexes;":[70],"FHD-286,":[72],"related":[74],"ATPase":[76,106,120,255],"inhibitor,":[77],"currently":[79],"being":[80],"explored":[81],"clinically":[82],"for":[83,180,266],"treatment":[85],"metastatic":[87],"uveal":[88],"melanoma":[89],"AML":[91,99,258],"(NCT04879017":[92],"NCT04891757).":[94],"Here":[95],"show":[97],"cell":[100,111],"lines":[101],"are":[102],"sensitive":[103],"inhibition,":[107],"resulting":[108,137],"both":[110],"cycle":[112],"arrest":[113],"apoptosis.":[115],"We":[116],"demonstrate":[117,152],"inhibition":[121,156],"primarily":[122],"affects":[123],"transcriptional":[126,245],"profile":[127],"by":[128],"regulating":[129],"genomic":[131],"occupancy":[132],"at":[133],"various":[134],"enhancer":[135],"elements,":[136],"downregulation":[139],"key":[141],"target":[142,162],"genes.":[143,163],"Using":[144],"vivo":[146],"mouse":[147],"models":[148],"AML,":[150],"dose-dependent":[153],"tumor":[154],"growth":[155],"pharmacodynamic":[158],"modulation":[159,169],"Together,":[164],"these":[165],"data":[166],"suggest":[167],"function":[172],"may,":[173],"part,":[175],"provide":[176],"mechanistic":[178],"basis":[179],"clinical":[182],"FHD-286":[185],"AML.":[187],"Citation":[188],"Format:":[189],"Gabriel":[190],"J.":[191,226],"Sandoval,":[192],"Katharine":[193],"Feldman,":[194],"Sal":[195],"Topal,":[196],"Ammar":[197],"Adam,":[198],"Hsin-Jung":[199],"Wu,":[200],"Darshan":[201],"Sappal,":[202],"Luis":[203],"M.":[204],"Soares,":[205],"David":[206],"L.":[207],"Lahr,":[208],"Lan":[209],"Xu,":[210],"Rishi":[211],"G.":[212,232],"Vaswani,":[213],"Jordana":[214],"Muwanguzi,":[215],"Liyue":[216],"Huang,":[217],"Jessica":[218],"Piel,":[219],"Mike":[220],"Collins,":[221],"Ho":[222],"Man":[223],"Chan,":[224],"Michael":[225],"Thomenius,":[227],"Steven":[228],"F.":[229],"Bellon,":[230],"Ryan":[231],"Kruger,":[233],"Carl":[234],"P.":[235],"Decicco,":[236],"Richard":[237],"C.":[238],"Centore,":[239],"Martin":[240],"Hentemann.":[241],"Modulation":[242],"program":[246],"contributes":[247],"preclinical":[250],"anti-tumor":[251],"activity":[252],"[abstract].":[259],"In:":[260],"Proceedings":[261],"American":[264],"Association":[265],"Cancer":[267,278],"Research":[268],"Annual":[269],"Meeting":[270],"2022;":[271],"2022":[272],"Apr":[273],"8-13.":[274],"Philadelphia":[275],"(PA):":[276],"AACR;":[277],"Res":[279],"2022;82(12_Suppl):Abstract":[280],"nr":[281],"LB190.":[282]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2022-06-16T00:00:00"}